| Literature DB >> 30891124 |
Brad M Savall1, Dongpei Wu2, Devin M Swanson2, Mark Seierstad2, Nyantsz Wu2, Jorge Vives Martinez3, Beatriz García Olmos3, Brian Lord2, Kevin Coe2, Tatiana Koudriakova2, Timothy W Lovenberg2, Nicholas I Carruthers2, Michael P Maher2, Michael K Ameriks2.
Abstract
This report discloses the discovery and characterization of imidazo[1,2-a]pyrazines and pyrazolo[1,5-c]pyrimidines as selective negative modulators of α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors (AMPARs) associated with transmembrane AMPAR regulatory protein γ-8. Imidazopyrazine 5 was initially identified as a promising γ-8 selective high-throughput screening hit, and subsequent structure-activity relationship optimization yielded subnanomolar, brain penetrant leads. Replacement of the imidazopyrazine core with an isosteric pyrazolopyrimidine scaffold improved microsomal stability and efflux liabilities to provide 26, JNJ-61432059. Following oral administration, 26 exhibited time- and dose-dependent AMPAR/γ-8 receptor occupancy in mouse hippocampus, which resulted in robust seizure protection in corneal kindling and pentylenetetrazole (PTZ) anticonvulsant models.Entities:
Year: 2018 PMID: 30891124 PMCID: PMC6421542 DOI: 10.1021/acsmedchemlett.8b00599
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345